World Health Organization raises concern about spread of mosquito-borne Chikungunya virus
World Health Organization
issued an urgent call for action on Tuesday to prevent a repeat of an epidemic of the mosquito-borne
chikungunya virus
that swept the globe two decades ago, as new outbreaks linked to the Indian Ocean region spread to Europe and other continents.
An estimated 5.6 billion people live in areas across 119 countries at risk from the virus, which can cause high fever, joint pain and long-term disability, Diana Rojas Alvarez, a medical officer at the WHO, told reporters in Geneva.
"We are seeing history repeating itself," she said, drawing parallels to the 2004-2005 epidemic, which affected nearly half a million people, primarily in small island territories, before spreading around the world.
The current surge began in early 2025, with major outbreaks in the same Indian Ocean islands which were previously hit, including La Reunion, Mayotte and Mauritius.
An estimated one-third of La Reunion's population has already been infected, Rojas Alvarez said. The virus is now spreading to countries such as Madagascar, Somalia and Kenya, and has shown epidemic transmission in Southeast Asia, including India.
Of particular concern is the increasing number of imported cases and recent local transmission within Europe.
There have been approximately 800 imported chikungunya cases in continental France since May 1, Rojas Alvarez said.
Twelve local transmission episodes have been detected in several southern French regions, meaning individuals were infected by local mosquitoes without having travelled to endemic areas. A case was also detected last week in Italy.
Chikungunya, for which there is no specific treatment and which is spread primarily by
Aedes mosquito
species, including the "tiger mosquito" which also transmits dengue, and Zika, can cause rapid and large outbreaks. As the mosquitoes bite in the daytime, prevention is key, through the use of insect repellent and long-sleeved clothing.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
Move on HPV vaccine rollout to adolescent girls raises other vaccination priorities for Kerala: epidemiologists
Kerala's decision to introduce HPV vaccination targeting adolescent girls, to protect them from cervical cancer is generally hailed as a positive public health measure. However, health experts have pointed out that the State has other pressing public health concerns, where also vaccination strategies must be prioritised. Going by the current data from the population-based and hospital-based cancer registries in Kerala, the incidence of cervical cancer has been on a steady decline in the State over the past several years and it no longer figures among the top five cancers affecting women in Kerala, according to epidemiologists. This is consistent with improvements in women's health and hygiene, better sexual practices, education and healthcare access in Kerala. Even though the World Health Organization (WHO) has recommended HPV vaccination for adolescent girls, in Kerala cervical cancer incidence is only eight per lakh population, even when at the national level, cervical cancer remained the second highest of all cancers reported amongst women as in 2022. 'Only if there is an uptick' The committee headed by Dr. B. Ekbal, which submitted the State's Vaccine Policy recommendations in November 2022, had noted that HPV vaccination should be considered in Kerala only if there is an increasing trend in the incidence of cervical cancer from the current baseline. It said that given the fact that the cost of vaccinating 13 lakh adolescent girls would be over ₹200 crore, HPV vaccination was not indicated, nor was it cost effective. Dr. Ekbal says that this picture has changed given that Serum Institute of India is now producing HPV vaccines at much competitive rates. While HPV vaccine manufactured by pharma majors are available in the range of ₹2,000-₹4,000/dose (there is also the HPV vaccine which protects against nine strains of HPV, costing around ₹10,850/dose), Cervavac produced by Serum Institute of India is available at ₹2,000/dose. 'HPV vaccine cost has come down and as far as dosage is concerned, there is some emerging evidence, (as per the WHO), that even a single dose delivers solid protection against HPV. That changes the picture completely. From a gender perspective, I am happy about the State's decision to protect adolescent girls against HPV,' Dr. Ekbal said. Current public health concerns However, the State should not forget its current public health concerns, which included protecting children from rabies through anti-rabies pre-exposure prophylaxis vaccine and from mumps, through an additional dose of MMR vaccine, he said. Rabies is emerging as a serious public health issue in the State, with children being a major casualty, he reminded. 'The mortality and morbidity due to influenza and pneumococcal infections is high in the elderly, the immunocompromised and those with co-morbidities. The State should prioritise annual flu vaccine and pneumococcal vaccine to protect elderly against pneumonia and meningitis,' Dr. Ekbal pointed out. He said that the Health department should recommend these vaccines so that there is more uptake for the same, which can bring down the cost of vaccines. Time to push for elimination 'Introducing HPV for adolescent girls is a policy decision that the Government had taken much earlier. Questions whether HPV vaccination is a priority now can be controversial. It is true that cervical cancer incidence is going down steadily and thus this would be the right time to push through elimination strategies. HPV vaccination is being introduced as part of the State's efforts to eliminate cervical cancer and the operational details are being worked out,' PK Jameela, member, State Planning Board, said.
The Hindu
2 hours ago
- The Hindu
Tezpur University team develops low-cost device to detect tuberculosis
GUWAHATI A team of researchers from central Assam's Tezpur University has developed an affordable and portable device to detect tuberculosis (TB). The researchers said the device, using the autofluorescence or natural glow of the TB bacteria for detection instead of any chemical or dye, has been specially designed for use in rural and remote areas where advanced medical facilities are not easily available. Pabitra Nath of the university's Department of Physics and the team leader, said the device has a built-in heating system to improve test accuracy and can be operated using a smartphone. 'It costs under ₹25,000 and weighs less than 300 grams, making it a perfect fit for places with limited healthcare infrastructure,' he said. The other members of the team are Biprav Chetry and Chunuranjan Dutta, research scholars from Tezpur University's Department of Physics; J.P. Saikia and Santanu Goswami from the Department of Molecular Biology and Biotechnology; and Abhijit Gogoi from Labdig Innovations and Systems Private Limited. Early and accurate diagnosis is crucial in stopping the spread of TB, a major public health issue in India. The World Health Organization (WHO) and India's National TB Elimination Programme currently recommend LED fluorescence microscopy as the gold standard for TB screening. However, the standard testing method recommended by the WHO needs expensive machines and trained technicians, which are not available in many rural areas. The new device can solve this problem by making TB testing simpler and more accessible, the researchers said. 'While LED-FM offers higher sensitivity than conventional optical microscopy, it has several drawbacks. It depends on costly equipment, chemical staining agents like auramine-O, and trained personnel for sample preparation and interpretation. Furthermore, its reliance on laboratory infrastructure makes it impractical in many rural settings,' Professor Nath said. The device developed by the Tezpur University researchers leverages the principle of autofluorescence, a natural property of certain microbial cells, including Mycobacterium tuberculosis (mTB) cells, that emit a fluorescence signal when excited by a specific wavelength of light. 'The team's key innovation lies in the integration of a heating element within the sensor system. By raising the temperature of the bacterial sample, the system enhances the natural fluorescence signal from mTB cells, enabling trace-level detection without the use of stains or dyes,' Prof. Nath explained. The team has filed a patent for the device, and their study was published in Biosensors and Bioelectronics, an international journal.
Business Standard
2 hours ago
- Business Standard
Mustela Brings Family Skincare Breakthrough into the Spotlight at Upcoming Event
VMPL New Delhi [India], July 29: As part of its ongoing commitment to families and the planet, (Mustela), the iconic French skincare brand for the entire family, is proud to present its latest innovations and brand highlights at the upcoming parenting and wellness event. With a legacy rooted in dermatological science and a strong environmental conscience, Mustela is redefining how families approach skincare -- from newborns to parents. Certified B Corp - A Purpose-Driven Skincare Brand Mustela is "B Corp certified", a seal of trust that denotes compliance with the world's highest standards of social, environmental, and ethical accountability. This exclusive certification confirms Mustela's integrated business philosophy -- where people, planet, and purpose are as important as profit. From open-source sourcing to community support programs, Mustela's B Corp certification speaks to its commitment to nurturing families while safeguarding the planet they inherit. Our Mission: Worry-Free Skincare for Every Parent Parenting is riddled with challenges -- but skincare needn't be one of them. Mustela seeks to make things easier with dermatologist-tested products that work to calm everyday skin issues like nappy rashes, hard water impact, dry spots, redness, and sun sensitivity. Each formula is crafted to provide gentle, safe, and efficient care -- even on the most sensitive newborn skin. Eco-Designed With Love for the Planet Each step of Mustela's production process is infused with sustainability. The brand is proud to utilize: -Recyclable bottles and less packaging waste -Sustainable, FSC-certified cardboard printed using vegetable oil-based ink -Lighter packaging without instruction leaflets, lowering paper consumption and carbon emissions These environmentally mindful decisions are proof of Mustela's dedication to safeguarding generations to come by minimizing its footprint on the planet today. Nature-Powered & Science-Backed Every Mustela product is designed using natural-origin ingredients, a majority of which are plant-based and organic. With 59 publications and 14 patents behind them, Mustela's formulas have over 70 years of dermatological wisdom to back up their safety and effectiveness for every type of skin. Tailored Skincare for Every Skin Type Mustela knows that each baby is different -- and so is their skin. That's why the brand has a complete range specially developed for four skin types: Normal Skin - simple day-to-day care Dry Skin - moisturizing and nutrition Very Sensitive Skin - fragrance-free, extremely gentle care Atopic-Prone Skin - specifically developed to care for eczema-prone skin Product Highlights of the Event During the event, Mustela will present single solution Skin Care products, such as: SPF Sun Lotion - safe, broad-spectrum sun protection for the entire family 2-in-1 Cleansing Gel - extremely gentle hair and body wash, also suitable for newborns Stelatopia Range - comfort care for eczema and atopic skin Gentle Shampoo - tear-free formula ideal for daily use These products embody Mustela's commitment to blending science, nature, and care -- in service to the youngest, most sensitive among us. For parents in search of reliable, environmentally friendly skincare, Mustela remains a brand of preference -- one that shields not only skin, but also the planet.
